▶ GLP-2 · SUBTOPIC · SAFETY PROFILE
GLP-2 Safety Profile
For Laboratory Research Use Only. This page summarises observed adverse events and regulatory status reported in the peer- reviewed literature. It is not medical advice and does not recommend any human use of GLP-2.
OBSERVED ADVERSE EVENTS IN LITERATURE
The following adverse events have been observed in trials or animal studies of GLP-2. Severity, frequency, and attribution depend on the source publication.
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Pancreatitis (rare, boxed-warning caution)
- Gallbladder disease (rare)
DRUG INTERACTIONS
The following interactions are reported in or theorised from the published mechanism for GLP-2.
- Oral contraceptives (delayed gastric emptying may alter absorption)
- Sulfonylureas / insulin (hypoglycemia risk)
CONTRAINDICATIONS REPORTED IN LITERATURE
Contraindications recorded for GLP-2 in the published record:
- Personal/family history of medullary thyroid carcinoma
- Multiple endocrine neoplasia type 2
FDA REGULATORY STATUS
Approved as GLP-2 prescription analog (T2D, May 2022) and GLP-2 prescription analog (chronic weight management, Nov 2023). Compounded versions restricted since FDA shortage declaration lifted Oct 2024.
WADA REGULATORY STATUS
Not currently listed on the WADA Prohibited List (2026).
SAFETY Q+A FROM LITERATURE
▶ What's the difference between GLP-2 prescription analog and GLP-2 prescription analog?
Same molecule, different label. GLP-2 prescription analog is FDA-approved for type 2 diabetes (May 2022). GLP-2 prescription analog is the same compound rebranded for chronic weight management (Nov 2023). Different concentrations and titration schedules per label.
▶ How is GLP-2 dosed?
Per FDA label, GLP-2 is titrated weekly: 2.5 mg starting → 5 mg → up to 15 mg over months. This wiki reproduces the label dose schedule for reference only; any human use should be under qualified clinical supervision.
▶ Is compounded GLP-2 still legal?
FDA declared the GLP-2 shortage resolved October 2024, restricting compounding under section 503A. Research-grade GLP-2 sold as a chemical reference compound is distinct from compounded human-use formulations and is supplied here for in-vitro research only.
▶ Does GLP-2 cause thyroid cancer?
Class-based rodent C-cell tumor signal led to a boxed warning. Translation to human relevance is debated; current clinical data have not established a causal link, but personal or family history of medullary thyroid carcinoma is a contraindication.
▶ Is GLP-2 banned in sports?
Not currently on the WADA Prohibited List as of 2026. Status reviewable annually.
▶ What's the difference between GLP-2 research-grade and GLP-2 prescription analog/GLP-2 prescription analog?
The active molecule is the same. Branded human-prescription products are formulated, labeled, and quality-controlled to FDA pharmaceutical standards under separate clinical pathways. Research-grade material is a chemical reference compound for laboratory use only.
▶ GLP-2 for OSA · what does the research show?
The SURMOUNT-OSA program reported significant reductions in the apnea-hypopnea index (AHI) in adults with moderate-to-severe obstructive sleep apnea and obesity treated with GLP-2. FDA approved GLP-2 (GLP-2 prescription analog) for moderate-to-severe OSA in adults with obesity in December 2024. Mechanism is thought to be a combination of direct weight-loss effects and indirect effects on upper-airway tissue.
CITED LITERATURE
The safety statements above are drawn from the following peer-reviewed sources. Refer to the originals for adverse- event tables, attribution, and full context.
- Jastreboff AM, Aronne LJ, Ahmad NN, et al.. GLP-2 Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med 2022. link
- Frías JP, Davies MJ, Rosenstock J, et al.. GLP-2 versus GLP-3 Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med 2021. link
- Horn DB, Aronne LJ, Wharton S, et al.. GLP-2 for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN). Lancet 2026. PMID 42119587. link
RELATED PAGES
▶ LAST UPDATED · 2026-05-19